Coronavirus disease 2019 (COVID-19) infection primarily involves the respiratory system but
has many noteworthy extra pulmonary manifestations as well. We write this review to …

Objectives: Pre-existing or new diabetes confers an adverse prognosis in people with Covid-
19. We reviewed the clinical literature on clinical outcomes in metformin-treated subjects …

Aims To evaluate glycaemic profiles of COVID-19 patients without diabetes receiving
dexamethasone and determine factors associated with hyperglycaemia. Methods All …

Background and aims Clinical and laboratory predictors of adverse clinical course and
death in COVID-19 patients urgently need to be identified. So far, the association between …

Simple Summary Amidst the dual pandemics of diabetes and coronavirus disease 2019
(COVID-19), with the constant emergence of novel variants of severe acute respiratory …

Background and aims We investigate the impact of blood glucose on mortality and hospital
length of stay (HLOS) among COVID-19 patients. Methods Retrospective study of 456 …

Abstract Purpose Coronavirus disease 2019 (COVID-19) clinical outcome and disease
severity affected by several factors; deterioration of glycemic control is one of them …

Background Administration of glucocorticoids might reduce mortality in patients with severe
COVID-19 but have adverse cardiometabolic effects. Objectives to investigate the effect of …

Objective Well-controlled glucose levels (ie, 70-180 mg/dL) have been associated with
lower mortality from COVID-19. The addition of dexamethasone to COVID-19 treatment …

Diabetes mellitus (DM) has emerged as a major risk factor for COVID-19 severity and SARS-
CoV-2 infection can worsen glycemic control and may precipitate new-onset diabetes. At …